-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Original title: Rhine Bio: Shanghai Xiangchu Asset Investors investigated our company on June 16
On June 20, 2022, Rhine Biotech (002166) announced that: Shanghai Xiangchu Asset Liu Junyang investigated our company on June 16, 2022
The main contents of this research:
Q: How will the passage of the US MORE Act and CAOA Act affect the company's industrial hemp business? What is the current progress of the US industrial hemp industry regulations and the application of downstream brands?
Q: How will the passage of the US MORE Act and CAOA Act affect the company's industrial hemp business? What is the current progress of the US industrial hemp industry regulations and the application of downstream brands?A: The passage of the US MORE Act and the CAOA Act will have a positive effect on the company's industrial hemp project.
Q: Can you introduce the current revenue and business plan of the company's industrial hemp project?
Q: Can you introduce the current revenue and business plan of the company's industrial hemp project?A: This year, the company's industrial hemp project revenue goal is to break even.
Q: How does the company and Firmenich price its natural sweetener products?
Q: How does the company and Firmenich price its natural sweetener products?A: The company and Firmenich will negotiate the transaction price of natural sweetener products in the coming year at a specific time period (usually the raw material acquisition season) according to the raw material acquisition in the current year and the forecast of the market in the coming year.
Q: How can the company and Firmenich complete the contract with a guaranteed minimum amount of US$345 million within 5 years? Will the two parties renew the natural sweetener business contract?
Q: How can the company and Firmenich complete the contract with a guaranteed minimum amount of US$345 million within 5 years? Will the two parties renew the natural sweetener business contract?A: In 2018, the company signed a major strategic cooperation agreement with Firmenich, which was also the first time Firmenich entered the field of natural sweeteners.
Q: What is the main goal of the company's current natural sweetener business?
Q: What is the main goal of the company's current natural sweetener business?A: At this stage, the main goal of the company's natural sweetener business is to make the market bigger and stronger together with its peers, so that natural sweeteners can truly be known to consumers, empower consumer brands, and increase market share
The main business of Rhine Biotech is the production of high-purity monomers and standardized extracts of plant functional ingredients such as mogrosides, proanthocyanidins, anthocyanins, and Lycium barbarum polysaccharides
According to the 2022 quarterly report of Rhine Biosciences, the company's main income was 282 million yuan, up 27.
The stock has been rated by 4 institutions in the past 90 days, with 3 buy ratings and 1 overweight rating; the average institutional target price in the past 90 days is 11.
The following is the detailed profit forecast information:
Margin financing and securities lending data show that the stock has a net financing inflow of 137 million in the past three months, and the financing balance has increased
The above content is organized by Securities Star based on public information.
Editor:
